Business Context and Reporting Period
This Form 8-K Current Report was filed by Contineum Therapeutics, Inc. (CTNM) on March 17, 2025, reporting events occurring on March 14, 2025. The Company is a Delaware corporation listed on the Nasdaq Global Select Market and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The primary material change reported is the appointment of Diego Miralles, M.D., to the Board of Directors, effective March 14, 2025. Dr. Miralles serves as a Class II director with a term expiring at the 2026 annual meeting. Concurrently, the Company terminated a prior advisor agreement with Dr. Miralles that had been in effect since June 2024.
Guidance, Outlook, and Management Commentary
The filing provides no financial guidance, outlook, or management commentary regarding business operations. It details the following regarding Dr. Miralles:
- Independence Status: The Board determined Dr. Miralles is not independent under Nasdaq listing standards due to his prior advisor relationship and compensation.
- Committee Service: Dr. Miralles was not appointed to any Board committees at the time of this filing.
- Compensation: As a non-employee director, Dr. Miralles will receive cash and equity compensation under the existing Non-Employee Director Compensation Program, including an initial option grant for 29,500 shares of Class A common stock.
- Prior Arrangement: The terminated advisor agreement previously provided a monthly retainer (reduced from $16,000 to $10,000) and an option for 5,000 shares at an exercise price of $17.92 per share.
Investor Verification Checklist
- Verify the independence status of the Board of Directors following the appointment of Dr. Miralles.
- Review the terms of the Non-Employee Director Compensation Program to understand the valuation of the 29,500 share option grant.
- Confirm the composition of the Class II directors, now consisting of Dr. Miralles, Ms. Lyons-Williams, and Mr. Schimmelpennink.
- Check for any future filings regarding committee assignments for Dr. Miralles.